Skip to main content
Fig. 3 | Journal of Nanobiotechnology

Fig. 3

From: Bone-targeted erythrocyte-cancer hybrid membrane-camouflaged nanoparticles for enhancing photothermal and hypoxia-activated chemotherapy of bone invasion by OSCC

Fig. 3

Characterization and drug release of Asp8[H40-TPZ/IR780@(RBC-H) NPs in vitro. a TEM images of H40-TPZ/IR780 NPs and b Asp8[H40-TPZ/IR780@(RBC-H) NP. c Average size and d surface zeta potential of bare H40-TPZ/IR780 NPs and Asp8[H40-TPZ/IR780@(RBC-H) NPs. The data are presented the average ± standard deviation (n = 3). e Release profiles of IR780 from the Asp8[H40-TPZ/IR780@(RBC-H)] NPs in different pH (5.0 and 7.4) buffer with or without laser irradiation. f Hemolysis assay of Asp8[H40-TPZ/IR780@(RBC-H)] NPs compared with RBC-H hybrid membrane vesicles, H40-TPZ/IR780 NPs, and dextran. 1 % Triton X-100 was used as a 100% hemolytic value. g CLSM and h relative fluorescence intensity analysis of ROS generation and hypoxia of WSU-HN6 incubated with PBS, Asp8[H40-TPZ/IR780@(RBC-H)] NPs without (A) and with (B) laser irradiation, Pyo (C), and DFO (D) for different time using Image J (scale bar = 25 μm)

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us